NewClin

NewClin transforms clinical research.

We harness the power of technology and data to develop and commercialize transforming solutions that increase the pace and productivity of clinical research. Our customers are the stakeholders of the 61,000 active clinical trials worldwide.

Our ultimate goal is to boost science dissemination and shorten therapeutic innovation time-to-market for the benefit of patients, physicians and industry.

NewClin is currently developing two innovative solutions:

• GoClin, the 1st global platform aimed at an early, free and personalized access to therapeutic innovation through clinical research. It is based upon a deeptech backbone: the worldwide exclusive license of an AI-driven Q/A chatbot combined with the license of clinical research APIs/databases with no international equivalent. Such solution has already drawn attention from two large US companies. The market we adress is that of healthcare big data ($14.25Bn, expected $68.75Bn in 2025);
• AppClin, the most comprehensive mobile & web application suite for the acceleration and productivity of clinical research. It relies upon IA, mobile technologies and geolocation and will comprise 6 interoperable apps. The first one is already available and has been licensed to an academic clinical research group, other prospects being interested. The principal market we adress is that of mobile apps for patient enrolment ($ 4.8MBd, +15% CAGR)